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Abstract 
Background: The diagnosis of extra-pulmonary tuberculosis (EPTB) by conventional methods such as culture and microscopy has low 
sensitivity and requires an invasive procedure. A simple rapid serological test would be of great value. 
Methodology: Six antigens (ESAT-6, Ag85A, TB10.4, Rv3881c, lipoarabinomannan (LAM) and Ara6-BSA) were tested in an ELISA to 
detect antigen-specific IgG and IgM antibodies in sera from 54 culture- and histology-confirmed tuberculous lymphadenitis (TBLN) patients 
as follows: four were HIV seropositive; sera from 25 was smear positive for pulmonary tuberculosis (PTB); 15 were culture- and histology-
negative lymphadenitis (non-TBLN) patients; and 22 werehealthy controls (HCs). 
Results: The sensitivities of the antigens for the detection of IgG in sera of TBLN patients ranged from 4% to 30%. Specificities ranged from 
73% to 100% with sera from non-TBLN patients and 91% to 100% with sera from HCs. Sensitivities of the antigens for detection of IgM 
ranged from 0% to 15% and specificities ranged from 80% to 100% with sera from non-TBLN patients and 91% to 100% with sera from 
HCs. LAM was the most potent antigen for detection of IgG. When LAM and ESAT-6 were combined, sensitivity increased up to 43% and 
specificity with non-TBLN was 80% with HC 96%. 
Conclusions: The study suggests that the combined use of LAM and ESAT-6 for IgG antibody detection in sera from TBLN patients could be 
a supplement to microscopy of fine-needle aspirate (FNA) to diagnose TBLN among patients suspected of TBLN.  
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Introduction 
Tuberculosis (TB) is a major public health 
problem in Ethiopia. According to the World Health 
Organization (WHO) report of 2008 [1], Ethiopia is 
number 7 among the 22 high TB-burden countries. 
Primarily considered a pulmonary disease, TB can 
affect almost any organ. According to the Ethiopian 
National TB and Leprosy Control program (NTLC) 
[2], pulmonary TB (PTB) accounts for 63% of all TB 
cases and extra-pulmonary TB (EPTB) accounts for 
37% of cases, with 80% of EPTB being lymph node 
TB [2]. In spite of these high numbers, diagnosis of 
tuberculous lymphadenitis (TBLN) remains a 
challenge. 
The clinical signs and symptoms of EPTB are 
non-specific [3] and both culture and microscopy 
using Ziehl-Neelsen (ZN) staining to detect acid-fast 
bacteria (AFB) have low sensitivity as most cases are 
paucibacillary [4]. The polymerase chain reaction 
(PCR) is sensitive and specific but expensive and not 
available in the majority of health care centers in 
resource-poor countries. Moreover, these tests involve 
an invasive procedure to obtain clinical specimens 
[5]. Thus there is a great need to develop simple, 
rapid, affordable and user-friendly methods to 
diagnose EPTB. Serological tests would be of great 
value in resource-poor settings and there are 
commercial serological tests available that may be 
used in the diagnosis of EPTB but they are highly 
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variable with respect to sensitivity (0 to 100%) and 
specificity (59 to 100%) [6]. 
This study evaluated the diagnostic potential of 
six antigens, early secretory antigenic target-6 
(ESAT-6), antigen 85A (Ag85A), TB10.4, Rv3881c, 
LAM and Ara6-BSA, by using sera from TBLN 
patients, healthy controls (HCs), non-tuberculous 
lymphadenitis (non-TBLN) cases and PTB patients. 
Previous studies have reported that Ag85A, Rv3881c, 
LAM, Ara6-BSA and ESAT-6 may be useful for the 
serodiagnosis of pulmonary and bovine TB 
respectively [7-11]. Ag85A, ESAT-6 and TB10.4 are 
strongly recognized by T-cells isolated from TB 
patients and have been seen to induce a robust cell 
mediated immune response [7,12,13]. However, little 
is known about the diagnostic potential of these 
antigens in EPTB. The purpose of the study was to 
assess the potential of the six antigens and to identify 
the most potent single and/or combined antigens to 
differentiate between TBLN and non-TBLN patients 
using ELISA.  
 
Materials and Methods 
Study Participants 
Ethical approval was obtained from 
AHRI/ALERT Ethical Committee (Reg.No.001/05) 
and the National Ethical Review Committee (NERC), 
(RDHE/190-64/2005), and the study was conducted 
from October 2005 until July 2006. Patients 18 years 
and above attending Butajira hospital, located l35 km 
south of Addis Ababa, 2) who had enlarged lymph 
nodes that did not respond to a course of broad 
spectrum antibiotics and were screened with the 
current diagnostic algorithm for TBLN in Ethiopia 
[14]; were considered for the study. All participants 
signed a written informed consent form. Patients who 
were critically ill, taking anti-TB drugs, had other 
forms of TB, were anemic, or had medical contra-
indications were excluded from the study. Among 
115 TBLN suspects considered for the study, 100 
were M. tuberculosis culture positive, 54 (proven 
TBLN) were culture and histology positive, 15 (non 
TBLN patients) were culture and histology negative, 
and 46 were excluded from the study by the exclusion 
criteria. The 54 proven TBLN and all the 15 non-
TBLN patients were included in the study. The 
number of non-TBLN cases was small in number. We 
therefore included, upon consent, sera from 25 PTB 
and 22 HCs who were 18 years and above and 
residing in the same locality. General physical 
examination confirmed that the HCs did not have 
signs and symptoms of TB. All of them were BCG 
vaccinated at birth as confirmed with BCG scar 
and/or BCG history. FNA and biopsy specimens were 
obtained from TBLN suspects and analyzed by 
culture, ZN staining and histology. Homogenized 
biopsies were processed and cultured according to the 
standard method on Löwenstein-Jensen (LJ) media 
containing glycerol and pyruvate. ZN staining on 
FNAs and sputum smears used the standard hot ZN 
technique to identify AFB positive cases. Histology 
was performed on formalin fixed biopsies embedded 
in paraffin blocks. Sections were cut and stained with 
haematoxylin and eosin (H&E). The presence or 
absence of granulomas was noted by a pathologist 
without the knowledge of culture and ZN staining 
results. All ZN positive TBLN patients were also 
positive by culture and/or histology. 
Blood samples were collected from TBLN 
suspects, PTB patients and HCs at the same time 
when the biopsy and FNA samples were taken for 
culture and ZN staining respectively. The sera were 
obtained by centrifugation and stored frozen at -20ºC 
until used for ELISA.  
 
Collection of blood specimens 
HIV counseling was given to the TBLN suspects 
and all of those included in our study consented to 
HIV testing prior to the drawing of 10 ml venous 
blood. 
 
HIV testing 
HIV testing was done for all TBLN suspects by 
using the diagnostic algorithm assay kit according to 
the manufacturer’s directions and following the 
national guidelines for HIV screening, Ministry of 
Health, Ethiopia. HIV testing was not done for PTB 
patients and healthy controls. 
 
ELISA 
Six different antigens were used for the ELISA: 4 
recombinant proteins, Rv3881c ESAT-6, Ag85A, 
TB10.4, lipoarabinomannan (LAM) and Ara6-BSA 
(with BSA as control). To optimize the appropriate 
antigen concentration, six different antigen 
concentrations (3 µg/ml, 2 µg/ml, 1 µg/ml, 0.5 µg/ml, 
0.25 µg/ml, 0.1µg/ml,) were tested using one TBLN 
serum, one non-TBLN serum, and one PTB serum. 
Sera were obtained from patients with or without TB 
as confirmed by culture, histology and microscopy, 
and tested in 5 dilutions from 1:100 to 1:500.  
The four recombinant proteins were produced as 
described previously [15,16]. LAM was prepared as 
described by Hamasur et al. [17]. Ara6-BSA, a 
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synthetic homologue of LAM, was prepared as 
described by Tong et al. [9]. The optimized 
concentrations, 0.5 µg/ml, 0.25 µg/ml, 0.25 µg/ml, 2 
µg/ml 0.5 µg/ml, 0.1 µg/ml,and 0.25 µg/ml of 
Rv3881c, ESAT-6, Ag85A, TB10.4, LAM, Ara6-BSA 
and BSA respectively were coated overnight onto 
flat-bottom ELISA plates (Greiner, Nürtingen, 
Germany) at 37ºC in  a water bath. Plates were then 
washed four times with phosphate buffered saline 
(PBS) containing 1% Tween 20 v/v (PBST), 2 x 
short/2 x soak for 2 to 5 minutes. One hundred µl per 
well of blocking solution (PBS containing 1% BSA 
(PBS 0.1% BSA) was added and incubated for one 
hour at 37ºC. Plates were then washed four times as 
before and 50 µl of serum diluted 1:200 in PBST with 
10% normal goat serum (NGS) was added and 
incubated at 37ºC for one hour. Accrual of serum 
samples was random. Plates were then washed four 
times and 50 µl of peroxidase conjugated rabbit 
antihuman IgG or IgM peroxidase conjugates 
(BioRad, France) diluted in PBST with 10% NGS 
was added to each well. The anti-human IgG 
conjugate was diluted 1:3000 and the anti-human IgM 
was diluted 1:1000. After washing four times, 50 µl 
of tetra methyl benzidine (TMB) substrate solution 
was added to each well. Optical density (OD) was 
read at 450 nm wavelength after stopping the reaction 
with 50 µl of 0.5M H2SO4, when the OD reading of 
BSA with the standard serum was 0.1 at 630 nm. The 
person who performed the ELISA was blind to the 
serum samples tested. 
 
Statistical analysis  
 
Sensitivity was calculated by dividing the 
number of positive sera by one or by the two 
combinations of antigens divided by the total number 
of sera from TBLN patients confirmed with histology 
and culture or the total number of sera from smear-
positive PTB patients x 100%. Specificity was 
calculated by dividing the number of negative sera by 
one or by the two combinations of antigens divided 
by the total number of sera from non-TBLN patients 
confirmed with culture and histology or the total 
number of sera from HCs x 100%. 
 
Results 
Figure 1 shows the scatter plots for IgG antibody 
detection against the six antigens using sera from 
HCs, TBLN patients, non-TBLN cases and PTB 
patients. Figure 2 shows the scatter plots for IgM 
antibody detection against the same antigens. Table1 
shows the sensitivities with sera from TBLN and PTB 
cases and specificities with sera from non-TBLN 
cases and HCs using IgG antibody test results with 
the six antigens and two combinations of antigens. 
Sensitivities with sera from TBLN cases for 
individual antigens ranged from 6 to 30%. 
Specificities ranged from 73% to 100% with sera 
from non-TBLN patients and from 91% to 100% with 
sera from HCs. Of the six antigens tested, LAM was 
found to be the single most potent antigen with a 
sensitivity of 30% and specificity of 100%. ESAT-6 
followed with a sensitivity of 13% and with a 
specificity of 96% when HC sera were considered as 
controls. The specificity was 80% for LAM and 96% 
for ESAT-6 when sera from non-TBLN patients were 
considered as a control. Furthermore, sensitivities 
were improved when different combinations of 
antigens were used. When LAM and ESAT were 
combined, sensitivity increased up to 43% and 
specificity with non-TBLN was 80% with HC 96%.   
Table 2 shows the sensitivities with sera from 
TBLN and PTB cases and specificities with sera from 
non-TBLN cases and HCs using IgM antibody test 
results with the six antigens and two combinations of 
antigens. When LAM was combined with ESAT-6, 
sensitivity was 9% and specificity 87% with non-
TBLN sera and 91% with sera from HCs. When 
LAM, ESAT-6 and Rv3881c were combined, 
sensitivity was 15% and specificity 87% with non-
TBLN sera and 91% with sera from HC. For all the 
six single antigens and the two combinations of 
antigens, IgM antibody detection was more sensitive 
in PTB patients than in TBLN. 
We did not find an association of HIV status with 
IgG or IgM antibody detection. Of the 54 proven 
TBLN patients included in our study, only 4 (7%) 
were AFB positive by ZN staining. 
 
Discussion 
This study was conducted to evaluate the 
diagnostic potential of four recombinant antigens 
(ESAT-6, Ag85A, TB10-4, and Rv3881c) as well as 
LAM and its synthetic homologue Ara6-BSA to 
differentiate between TBLN and non-TBLN patients. 
Lipoarabinomannan (LAM) was found to be the 
single most potent antigen among the six antigens 
tested for IgG antibody detection. ESAT-6 and 
Rv3881c gave the next highest sensitivity and 
specificity, respectively, following LAM. Ara6-BSA 
is among those which showed a relatively lower 
sensitivity and specificity. This observation could be 
due to the conformational differences between LAM  
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and Ara6-BSA. Antigenic conformation is one of the 
main attributes that determine formation of stable 
antigen-antibody complexes [18]. Of the six single 
antigens and the two combinations of antigens 
presented in Table 1, IgG antibody detection using the 
combination of LAM and ESAT-6 was the best to 
differentiate between TBLN and non-TBLN cases.  
A recent systematic review reported by Steingart 
et al. [6]
 
reported a variable estimate of sensitivity 
and specificity of 21 studies of commercial 
serological tests. Sensitivity ranged from 0% to 100% 
and specificity ranged from 59% to 100%, a range 
within which our findings fall as well.  
 
 
Toshinobu et al. [19]
 
showed that detection of 
anti-LAM antibody using MycoDot in pleural fluid is  
a specific diagnostic tool for tuberculous pleurisy and 
recommended it as simple, rapid, and cost-effective. 
Our finding that IgG anti-LAM antibody gave better 
sensitivity and specificity among the six antigens 
tested suggests its potential role as a target for the 
serodiagnosis of TBLN.  
IgG anti-LAM and anti-ESAT-6 appear more 
discriminating compared to IgG antibodies of  the 
other four antigens (Rv3881c, TB10.4, Ag85A and 
Ara6-BSA). Nevertheless, the sensitivities and  
 
Figure 1. Scatter plots for IgG antibody detection using sera from HC, TBLN, non-TBLN and PTB against the six 
antigens (Rv3881c, LAM, Ara6-BSA, Ag85A, ESAT-6, TB10.4) tested.  
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specificities obtained with IgG or IgM antibodies to 
each of the single antigens suggest that their 
diagnostic capacity is not optimal. However, the 
combination of LAM and ESAT-6 showed an 
increased sensitivity for the detection of IgG antibody 
when sera from non-TBLN cases were used as a 
control. Sensitivity increased to 43% and specificity 
was 80%.  Diagnosis of TBLN using the standard ZN 
microscopy for AFB requires 1x10
4 
bacilli per 
specimen [20]. However, since most TBLN cases are 
paucibacillary, detection of TBLN by ZN staining is 
difficult because of its extremely low sensitivity 
[3,4]. Therefore, since the sensitivity for IgG 
antibody detection improved when LAM and ESAT-
6 were combined, an antibody test on the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
combination of these antigens could be a useful 
supplement to ZN staining of FNA samples if further 
developed for routine use. However, the number of 
serum samples tested from both patients and controls 
was low. 
The low sensitivities obtained in our study may 
be due to the variation in antibody response against 
different antigens or it could also be due to variations 
in antigen expression under different conditions. 
Previous studies have reported that M. tuberculosis 
adapts to its environment by altering the profile of the 
genes that it expresses. This profile is modulated 
when the in vivo environment changes [21, 22]. Thus  
Figure 2. Scatter plots for IgM antibody detection using sera from HC, TBLN, non-TBLN and PTB against the six 
antigens (Rv3881c, LAM, Ara6-BSA, Ag85A, ESAT-6, TB10.4) tested.  
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selection of antigens of M. tuberculosis based on the 
antibody response of PTB patients alone might not 
provide the appropriate materials that can be used for 
the sero-diagnosis of EPTB.  
Although HIV could complicate the diagnosis of 
TB [23], there was no evidence of association of HIV 
with IgG or IgM antibody detection with the low 
number of HIV seropositives in our study, 4/54 (7%). 
A larger study with more HIV-positive subjects is 
recommended to assess the influence of HIV co-
infection on antibody detection in TBLN patients. 
A limitation of this study may be that the ELISA 
was performed on a limited number of sera, especially 
those in the non-TBLN patient group. Although we 
have managed to identify the best single and/or 
combined antigens, the identification may still be  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
suboptimal. Our study has investigated the antibody 
response to six antigens   using four groups of sera 
retrospectively and needs further testing prospectively 
to confirm the accuracy. Once specific and sensitive 
antigens have been identified in ELISA, a simple 
diagnostic test can be developed for routine use.   
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Antigens Sensitivity (%) 
Positive sera 
TBLN
1
 
Specificity (%) 
Negative sera 
non-TBLN
1
    
Specificity (%) 
Negative sera   
HC
1
  
Sensitivity (%) 
Positive sera 
PTB
1
 
ESAT-6        7/54 (13 %) 15/15 (100 %) 21/22 (96 %) 0/25 (0 %) 
Ag 85A    2/54 (4 %) 15/15 (100 %) 21/22 (96 %) 1/25 (4%) 
TB10.4           3/54 (6 %) 14/15 (93 %) 20/22 (91%) 3/25 (12 %) 
Rv 3881c     6/54 (11.%) 11/15 (73 %) 21/22 (96 %) 5/25 (20 %) 
LAM    16/54 (30 %) 12/15 (80 %) 22/22 (100 %) 7/25 (28 %) 
Ara6-BSA     6/54 (11 %) 11/15 (73 %) 20/22 (91 %) 3/25 (12 %) 
LAM &   ESAT6       23/54 (43 %)2 12/15 (80 %)
2
 21/22 (96 %)2 7/25 (28 %)
2
 
 LAM, ESAT-6  
&Rv3881c    
29/54 (54 %) 2           8/15  (53 %)
2
               20/22 (91 %)
2
                      12/25(48 %)
2
 
Antigens 
Sensitivity (%) 
Positive sera 
TBLN
1
 
Specificity (%) 
Negative sera 
non-TBLN
1
 
Specificity (%) 
Negative sera 
HC
1
 
Sensitivity (%) 
Positive- sera 
PTB
1
 
ESAT-6             5/54 (9 %) 13/15 (87 %) 21/22(96 %) 4/25 (16 %) 
Ag85A  5/54 (10 %)          12/15 (80 %)           21/22 (96 %)           4/25 (16%) 
TB10.4            3/54 (6 %)           14/15 (93%)              21/22 (96 %)            2/25 (8 %) 
Rv3881c 3/54 (6%)           14/15 (93 %)           22/22(100 %)                1/25 (16 %) 
LAM               0/54 (0 %)      15/15 (100 %)         21/22 (96 %)             1 /25 (16 %) 
Ara6-BSA       3/54 (6 %)          13/15 (87 %)        21//22 (96 %)                8/25 (32 %) 
LAM & ESAT.6           5/54 (9 %) 
2
         13/15 (87 %)
2
       20/22 (91 %) 
2
                5/25 (20 %)
2
 
LAM, ESAT-6 &    
Rv3881c  
8/54 (15 %)  
2
         13/15(87 %)
2 
      20/22 (91 %) 
2 
                6/25 (24 %) 
2
                                       
 
Table 1. Sensitivities and specificities of IgG antibody assays using sera from TBLN, non-TBLN, HC and PTB. 
 
1TBLN: tuberculous lymphadenitis, Non-TBLN: non-tuberculous lymphadenitis, HC: Healthy control, PTB: Pulmonary tuberculosis 
2Sensitivity of the combined antigens represented the percentage of patients who were positive by one or by all the antigens combined among histology and culture confirmed 
TBLN cases. Specificity represented the percentage of individuals who were negative by all the combined antigens among HCs or among culture and histology confirmed non-
TBLN cases. 
 
Table 2. Sensitivities and specificities of IgM antibody assays using sera from TBLN, non-TBLN, HC and PTB 
 
1TBLN: tuberculous lymphadenitis, Non-TBLN: non-tuberculous lymphadeniti   HC: Healthy control, PTB: Pulmonary tuberculosis. 
2Sensitivity of the combined antigens represented the percentage of patients who were positive by one or by all the antigens combined among histology and culture 
confirmed TBLN cases. Specificity represented the percentage of individuals who were negative by all the combined antigens among HCs or among culture and 
histology confirmed non-TBLN cases.  
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Rv3881c were a gift of Dr. A. Geluk, University of Leiden, 
Leiden, The Netherlands. 
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